8-K: Mirum Pharma's Hepatitis Delta Drug Shows Promise in Phase 2b Trial

Mirum Pharmaceuticals announced positive primary endpoint results from the Phase 2b AZURE-1 study of brelovitug for chronic hepatitis delta virus.

Summary

• Mirum Pharmaceuticals, Inc. announced that the primary endpoint was met in the Phase 2b portion of the AZURE-1 study for brelovitug, an investigational treatment for chronic hepatitis delta virus (HDV).
• The study evaluated brelovitug, a monoclonal antibody targeting hepatitis B surface antigen (HBsAg), in 53 patients over 24 weeks.
• In the 300 mg once weekly (QW) arm, 100% of patients achieved virologic response, and 45% met the primary composite endpoint of virologic response and ALT normalization.
• In the 900 mg once every four weeks (Q4W) arm, 75% achieved virologic response, and 35% met the primary composite endpoint.
• These results compare favorably to the 0% response rates in the delayed treatment arm.
• Brelovitug demonstrated robust antiviral activity and was well-tolerated across dose groups.
• Full results will be presented at the EASL Congress in May 2026.
• Topline data from Phase 3 studies (AZURE-1 and AZURE-4) are expected in H2 2026, with a potential BLA submission and U.S. launch in 2027.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive development due to the strong efficacy demonstrated in a difficult-to-treat disease and the clear path towards potential market entry.

Positives

• Primary endpoint met in Phase 2b AZURE-1 study for brelovitug in chronic HDV.
• 100% virologic response in the 300 mg QW arm at Week 24.
• 45% achievement of the primary composite endpoint (virologic response + ALT normalization) in the 300 mg QW arm.
• 75% virologic response in the 900 mg Q4W arm at Week 24.
• 35% achievement of the primary composite endpoint in the 900 mg Q4W arm.
• Demonstrated robust antiviral activity and was well-tolerated.
• Further reductions in ALT and HDV RNA levels observed after 24 weeks.
• Supports potential of brelovitug as a single-agent therapy for HDV.

Negatives

• The delayed treatment arm showed 0% virologic response and 0% achievement of the primary composite endpoint.
• One patient in the 900 mg Q4W arm experienced a serious adverse event (hospitalization for liver cirrhosis) which was deemed unrelated to treatment.

Risks

• Actual results may differ from forward-looking statements due to risks and uncertainties in pharmaceutical product development.
• Risks and uncertainties inherent in the Company's business, as described in other SEC filings.
• Potential for brelovitug to not achieve expected benefits.
• Uncertainty regarding the timing of BLA submission and commercial launch.
• Competition in the treatment of chronic hepatitis delta virus.

Future Outlook

Topline data from the Phase 3 AZURE-1 and AZURE-4 studies are expected in the second half of 2026. A potential Biologics License Application (BLA) submission and commercial launch in the U.S. are anticipated in 2027.

Management Comments

• The results support the potential of brelovitug as a single agent therapy to treat HDV.

Industry Context

StockSavvy.ai notes that the positive Phase 2b results for brelovitug in treating chronic Hepatitis Delta Virus (HDV) are significant, as HDV is a severe liver disease with limited treatment options. Success in this indication could position Mirum Pharmaceuticals as a key player in a niche but critical therapeutic area.

Stakeholder Impact

• Shareholders: Potential for increased company valuation and future revenue if brelovitug is approved and commercialized.
• Patients: Offers hope for a new, effective treatment for chronic Hepatitis Delta Virus, a severe liver disease.
• Healthcare Providers: Provides a new therapeutic option for managing HDV patients.

Next Steps

• Present full results from Phase 2b AZURE-1 study at EASL Congress (May 27-30, 2026).
• Report topline data from Phase 3 AZURE-1 and AZURE-4 studies (H2 2026).
• Potential BLA submission (2027).
• Potential U.S. commercial launch (2027).

Key Dates

Recommendation

The strong positive results from the Phase 2b study, demonstrating significant efficacy and tolerability for brelovitug in a disease with unmet needs, coupled with a clear development and commercialization timeline, warrant a strong buy recommendation for investors.

Keywords

Mirum Pharmaceuticals, brelovitug, Hepatitis Delta Virus, HDV, AZURE-1 study, Phase 2b trial, monoclonal antibody, antiviral activity